Literature DB >> 8120399

Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.

E Björling1, F Chiodi, G Utter, E Norrby.   

Abstract

The purposes of this study were to map the targets for neutralizing Abs in the HIV-2 glycoproteins with particular emphasis on the role of the V3 region. Sera obtained from guinea pig immunized with peptides representing five immunogenic regions of the envelope proteins were used in cross-neutralization experiments with nine HIV-2 isolates. Broad cross-neutralizing activity was elicited by immunization with two peptides representing the central and COOH-terminal portions of the HIV-2 V3 loop. Murine mAbs were established from animals immunized with two corresponding overlapping peptides. Six mAbs showed neutralizing activity against the homologous virus isolate SBL-6669. Peptide absorption experiments were performed to define the target regions for human neutralizing Abs in the HIV-2 envelope glycoproteins. A significant blocking of neutralizing activity of five HIV-2 Ab-positive sera was seen in the presence of two peptides corresponding to the V3 region. Two overlapping deletion sets of peptides, representing amino acids Ser311 and Arg337, were used to identify the role of individual HIV-2 V3 amino acids in the binding of polyclonal and mAbs. Two distinct antigenic sites were identified in this region, the first corresponding to a region including the conserved motif Phe-His-Ser (amino acid 315-317) and the second in proximity of the COOH-terminal cysteine Trp-Cys-Arg (amino acid 329-331). Potentially these two sites can interact to represent a single discontinuous antigenic site. Taken together, these results indicate that V3 is an important neutralizing domain of HIV-2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120399

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Conservation of human immunodeficiency virus type 1 gp120 inner-domain sequences in lentivirus and type A and B retrovirus envelope surface glycoproteins.

Authors:  I Hötzel; W P Cheevers
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

Authors:  A McKnight; C Shotton; J Cordell; I Jones; G Simmons; P R Clapham
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.

Authors:  S Andersson; O Larsen; Z Da Silva; H Linder; H Norrgren; F Dias; R Thorstensson; P Aaby; G Biberfeld
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.

Authors:  José Maria Marcelino; Pedro Borrego; Cheila Rocha; Helena Barroso; Alexandre Quintas; Carlos Novo; Nuno Taveira
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

5.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8.

Authors:  Hannes Uchtenhagen; Samer Sourial; Rosmarie Friemann; Mariethe Ehnlund; Anna-Lena Spetz; Robert A Harris; Chaithanya Madhurantakam; Adnane Achour
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27

7.  An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.

Authors:  M Mamounas; D J Looney; R Talbott; F Wong-Staal
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.

Authors:  S Matsushita; S Matsumi; K Yoshimura; T Morikita; T Murakami; K Takatsuki
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Authors:  Helena Barroso; Pedro Borrego; Inês Bártolo; José Maria Marcelino; Carlos Família; Alexandre Quintas; Nuno Taveira
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

10.  Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125.

Authors:  Hannes Uchtenhagen; Rosmarie Friemann; Grzegorz Raszewski; Anna-Lena Spetz; Lennart Nilsson; Adnane Achour
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.